Full Text:   <2329>

CLC number: R735.2

On-line Access: 

Received: 2005-04-21

Revision Accepted: 2005-05-22

Crosschecked: 0000-00-00

Cited: 17

Clicked: 5920

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2005 Vol.6 No.9 P.913-918


Role of CD97stalk and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients

Author(s):  LIU Yong, CHEN Li, PENG Shu-you, CHEN Zhou-xun, HOANG-VU C

Affiliation(s):  Department of Surgery, Second Affiliated Hospital, School of Medicine, Yangzhou University, Yangzhou 225001, China; more

Corresponding email(s):   yongliu901112@163.com, chenli_hz@yahoo.com

Key Words:  CD97stalk, CD55, Gastric carcinoma, Molecular markers

LIU Yong, CHEN Li, PENG Shu-you, CHEN Zhou-xun, HOANG-VU C. Role of CD97stalk and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients[J]. Journal of Zhejiang University Science B, 2005, 6(9): 913-918.

@article{title="Role of CD97stalk and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients",
author="LIU Yong, CHEN Li, PENG Shu-you, CHEN Zhou-xun, HOANG-VU C",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T Role of CD97stalk and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients
%A LIU Yong
%A PENG Shu-you
%A CHEN Zhou-xun
%J Journal of Zhejiang University SCIENCE B
%V 6
%N 9
%P 913-918
%@ 1673-1581
%D 2005
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2005.B0913

T1 - Role of CD97stalk and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients
A1 - LIU Yong
A1 - CHEN Li
A1 - PENG Shu-you
A1 - CHEN Zhou-xun
J0 - Journal of Zhejiang University Science B
VL - 6
IS - 9
SP - 913
EP - 918
%@ 1673-1581
Y1 - 2005
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2005.B0913

Objectives: To explore the mechanism of development and aggressiveness in gastric carcinomas by investigating the expression and role of CD97 and its cellular ligand CD55 in gastric carcinomas. Methods: Tumor and corresponding normal mucosal tissue, collected from 39 gastric carcinoma patients, were examined by immunohistochemistry and RT-PCR for the expression of CD97 and CD55. Results: CD97stalk was strongly stained on scattered tumor cells or small tumor cell clusters at the invasion front of gastric carcinomas. The expression of CD97stalk was frequently observed in tumors of stage I and T1 gastric carcinoma patients. The expression of CD97stalk between Stage I and Stage II, III, IV specimens showed significant difference (P<0.05), between T1 and T2, T3, T4 specimens also showed significant difference (P<0.05). Specimens with tumor invasion depth limited in mucosa of T1 specimens showed higher positive CD55 expression than specimens with the same tumor invasion depth in T2, T3, T4 specimens, the expression of CD55 between T1 and T2, T3, T4 specimens was significantly different (P<0.05). There was strong correlation between the distribution patterns of CD97stalk and CD55 on tumor tissues (r=0.73, P<0.05). Signet ring cell carcinomas frequently contained strong CD97stalk and CD55-staining. Conclusions: Our results suggest that CD97stalk is probably involved in the growth, invasion and aggressiveness of gastric carcinomas by binding its cellular ligand CD55. CD97stalk and CD55 could be useful as molecular markers for prognosis and therapy of gastric carcinoma patients.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1] Aust, G., Eichler, W., Laue, S., Lehmann, I., Heldin, N.E., Lotz, O., Scherbaum, W.A., Dralle, H., Hoang-Vu, C., 1997. CD97: A dedifferentiation marker in human thyroid carcinomas. Cancer Res., 57:1798-1806.

[2] Aust, G., Steinert, M., Schutz, A., Boltze, C., Wahlbuhl, M., Hamann, J., Wobus, M., 2002. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am. J. Clin. Pathol., 118(5):699-707.

[3] Boltze, C., Schneider-Stock, R., Aust, G., Mawrin, C., Dralle, H., Roessner, A., Hoang-Vu, C., 2002. CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of cryocut sections. Pathol. Int., 52:83-88.

[4] Brabletz, T., Jung, A., Hermann, K., Gunther, K., Hohenberger, W., Kirchner, T., 1998. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract., 194:701-704.

[5] Brabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L.A., Knuechel, R., Kirchner, T., 2001. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA, 98:10356-10361.

[6] Hamann, J., Vogel, B., van Schijndel, G.M., van Lier, R.A., 1996. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J. Exp. Med., 184(3):1185-1189.

[7] Hoang-Vu, C., Bull, K., Schwarz, I., Krause, G., Schmutzler, C., Aust, G., Dralle, H., 1999. Regulation of CD97 protein in thyroid carcinoma. Clin. Endocrinol. Metab., 84:1104-1109.

[8] Jaspars, L.H., Vos, W., Aust, G., van Lier, R.A., Hamann, J., 2001. Tissue distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens, 57:325-331.

[9] Kwakkenbos, M.J., Kop, E.N., Stacey, M., Gordon, S., Lin, H.H., Hamann, J., 2004. The human EGF-TM7 family: A postgenomic view. Immunogenetics, 55:655-666.

[10] Li, L., Spendlove, I., Morgan, J., Durrant, L.G., 2001. CD55 is over-expressed in the tumour environment. Br. J. Cancer, 84(1):80-86.

[11] Maruyama, K., Ochiai, A., Akimoto, S., Nakamura, S., Baba, S., Moriya, Y., Hirohashi, S., 2000. Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology, 59:302-309.

[12] Mcknight, A.J., Gordon, S., 1998. The EGF-TM7 family: Unsual structures at the leukocyte surface. Leukoc. Biol., 63:271-280.

[13] Mustafa, T., Klonisch, T., Hombach-Klonisch, S., Kehlen, A., Schmutzler, C., Koehrle, J., Gimm, O., Dralle, H., Hoang-Vu, C., 2004. Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int. J. Oncol., 24(2):285-294.

[14] Niehans, G.A., Cherwitz, D.L., Staley, N.A., Knapp, D.J., Dalmasso, A.P., 1996. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol., 149(1):129-142.

[15] Nowicki, S., Nowicki, B., Pham, T., Hasan, R., Nagamani, M., 2001. Expression of decay accelerating factor in endometrial adenocarcinoma is inversely related to the stage of tumor. Am. J. Reprod. Immunol., 46(2):144-148.

[16] Remmele, W., Stegner, H.E., 1987. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe, 8:138-140.

[17] Shimo, K., Mizuno, M., Nasu, J., Hiraoka, S., Makidono, C., Okazaki, H., Yamamoto, K., Okada, H., Fujita, T., Shiratori, Y., 2004. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma. Gastroenterol. Hepatol., 19(6):643-647.

[18] Steinert, M., Wobus, M., Boltze, C., Schutz, A., Wahlbuhl, M., Hamann, J., Aust, G., 2002. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am. J. Pathol., 161:1657-1667.

[19] Wobus, M., Vogel, B., Schmucking, E., Hamann, J., Aust, G., 2004. N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int. J. Cancer, 112:815-822.

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE